Retinitis Pigmentosa

A 65-year-old man presented to the retina service for a preoperative cataract surgery evaluation after being followed for years for presumed retinitis pigmentosa.

Catch up on the top Healio Video Perspectives from this year’s Association for Research in Vision and Ophthalmology meeting.

FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Paulo E. Stanga, MD, explains how the Bionic Eye System provides artificial vision for patients with vision loss due to inherited retinal diseases.

FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Christine Kay, MD, discusses MCO-010, a gene-agnostic therapy for patients with advanced retinitis pigmentosa.

FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Charles C. Wykoff, MD, PhD, provides an overview of the Bionic Eye System for late-stage retinitis pigmentosa.

FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Ash Attia, PhD, of Bionic Vision Technologies discusses a novel suprachoroidal retinal prosthesis for retinitis pigmentosa.

Since 1949, May has been designated Mental Health Awareness Month, a time to address the challenges faced by millions of individuals experiencing mental health conditions, according to the National Alliance on Mental Illness.

MCO-010 demonstrated positive topline results in vision improvement in patients with permanent and severe vision loss from advanced retinitis pigmentosa, according to a press release from Nanoscope Therapeutics.

Beacon Therapeutics announced the presentation of interim safety and efficacy results from the phase 2 SKYLINE trial evaluating AGTC-501 gene therapy for X-linked retinitis pigmentosa.

Kiora Pharmaceuticals has entered into a strategic agreement that grants Théa Open Innovation development and commercialization rights to KIO-301 for the treatment of degenerative retinal diseases.